Clinical Pilot Study Will Test Anti-inflammatory Drug for ALS

November 8, 2013

The ALS Association and the Neurological Clinical Research Institute (NCRI) of Massachusetts General Hospital are pleased to announce a partnership for funding a clinical pilot study of tocilizumab, an anti-inflammatory drug. The partnership is part of an initiative to encourage the use of biomarkers in Phase II clinical trials to strengthen trial outcomes.

The study will test whether tocilizumab can slow disease progression in people with ALS and will be led by Shafeeq Ladha, M.D., of the Barrow Neurological Institute in Phoenix, Ariz., and Richard Barohn, M.D., of Kansas University Medical Center in Kansas City, Kan.

“There is an urgent need for better ALS treatments and therapeutic agents,” said Lucie Bruijn, Ph.D., Chief Scientist for The Association. “This pilot study will determine whether this drug, already approved for rheumatoid arthritis, can offer benefit in ALS.”

The MGH NCRI will provide study project and data management. The State University of New York, Upstate, will provide study monitoring and outcome measure training. Sites will be selected from the Northeast ALS Consortium (NEALS), a nationwide group of ALS clinical researchers with a long history of partnership with The ALS Association.

“The NCRI and The ALS Association are extremely well-positioned to work with both academic and industry partners to rapidly bring the best ALS science into clinical testing,” said Merit Cudkowicz, M.D., Chief of Neurology at Massachusetts General and Director of NCRI. NCRI serves as the coordinating center for NEALS.

Clinical studies funded through the program must include measurement of pharmacodynamic markers, also known as biomarkers, to determine whether the treatment has altered its intended molecular target and to collect tissue samples for detailed analysis of response to therapy. In the tocilizumab study, researchers will measure inflammatory gene changes in blood cells and cerebrospinal fluid. Inflammation is thought to be a central part of the ALS disease process.

The study is funded through a partnership agreement between The ALS Association and NRCI to develop novel, high-potential treatments for people with the disease.

Read the press release.

Powered by Blackbaud
nonprofit software